Genmab | GEN - Current Liabilities


Genmab reported DKK1.14B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Almirall EUR 323.65M 26.99M Jun/2026
Amarin USD 175.14M 10.94M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
argenx SE USD 1.58B 254.81M Jun/2026
AstraZeneca USD 31.27B 286M Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Demant DKK 12.42B 5B Jun/2026
Exelixis USD 411.88M 49.95M Sep/2026
Fresenius Medical Care EUR 7.91B 727.93M Sep/2026
Genmab DKK 1.14B 38M Jun/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
GN Store Nord DKK 10.82B 4.86B Sep/2026
GRIFOLS EUR 2.3B 59M Sep/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Insmed USD 596.57M 157.83M Sep/2026
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Lonza CHF 3.57B 421M Dec/2025
Merck EUR 8.96B 833M Sep/2026
Novartis USD 32.52B 777M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 29.77B 2.16B Sep/2026
UCB EUR 4.4B 470M Dec/2025